Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895425 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL6882257 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL8896667 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL8896941 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL11249237 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL7828971 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL7841880 | 1.00 | DGKA (0.68) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL616258 | 0.98 | DGKA (0.64) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL7840375 | 0.94 | DGKA (0.71) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL1888899 | 0.94 | DGKA (0.71) | DGKANAAAPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945556-A | Lipidoids for nucleic acid transfection and uses thereof | 捷克有机化学和生物化学研究院 | 2022-08-26 | — | — | CN | disclosed |
| CN-111278896-A | Thermosetting resin composition and method for producing same | 堺化学工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| EP-2319882-B1 | POLYOLEFIN RESIN COMPOSITION | ADEKA CORP (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-8288462-B2 | Polyolefin resin composition | ADEKA CORPORATION (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20110218279-A1 | POLYOLEFIN RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2011-09-08 | — | — | US | disclosed |
| EP-2319882-A1 | POLYOLEFIN RESIN COMPOSITION | Adeka Corporation (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-0751133-B1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5670563-A | ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND | CIBA-SPECIALTY CHEMICALS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | DGKA 3633/4885NAAA 145/4885PRSS1 144/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | DGKA 3658/4885NAAA 140/4885PRSS1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.